RRMS
MCID: RLP002
MIFTS: 46

Relapsing-Remitting Multiple Sclerosis (RRMS) malady

Neuronal diseases category

Summaries for Relapsing-Remitting Multiple Sclerosis

About this section
Sources:
9Disease Ontology, 34MalaCards
See all sources

Fully expand this MalaCard

Download this MalaCard
Disease Ontology:9 A multiple sclerosis that is characterized by relapse (attacks of symptom flare-ups) followed by remission (periods of recovery). symptoms may vary from mild to severe, and relapses and remissions may last for days or months. more than 80 percent of people who have ms begin with relapsing-remitting cycles.

MalaCards: Relapsing-Remitting Multiple Sclerosis, also known as multiple sclerosis, relapsing-remitting, is related to multiple sclerosis and optic neuritis. An important gene associated with Relapsing-Remitting Multiple Sclerosis is IFNB1 (interferon, beta 1, fibroblast), and among its related pathways is Immune response Bacterial infections in normal airways. The drugs glatiramer acetate and glatiramer and the compounds tarc and ccl3 have been mentioned in the context of this disorder. Affiliated tissues include t cells, brain and b cells, and related mouse phenotypes are nervous system and homeostasis/metabolism.

Aliases & Classifications for Relapsing-Remitting Multiple Sclerosis

About this section
Sources:
9Disease Ontology, 46Novoseek, 63UMLS, 36MeSH, 59SNOMED-CT
See all sources

Classifications:

Malacards categories (disease lists): (See all malacards categories)
Anatomical: Neuronal diseases


Aliases & Descriptions:

relapsing-remitting multiple sclerosis 9
multiple sclerosis, relapsing-remitting 63
multiple sclerosis relapsing-remitting 46
relapsing-remitting ms 9
rrms 9


External Ids:

Disease Ontology9 DOID:2378
SNOMED-CT59 426373005
MeSH36 D020529

Related Diseases for Relapsing-Remitting Multiple Sclerosis

About this section
Sources:
18GeneCards, 19GeneDecks
See all sources

Graphical network of the top 20 diseases related to Relapsing-Remitting Multiple Sclerosis:



Diseases related to relapsing-remitting multiple sclerosis

Symptoms for Relapsing-Remitting Multiple Sclerosis

About this section

Drugs & Therapeutics for Relapsing-Remitting Multiple Sclerosis

About this section
Sources:
6CenterWatch, 43NIH Clinical Center, 7ClinicalTrials, 63UMLS, 42NDF-RT
See all sources

Approved drugs:

Search CenterWatch for Relapsing-Remitting Multiple Sclerosis

Drug clinical trials:

Search ClinicalTrials for Relapsing-Remitting Multiple Sclerosis

Search NIH Clinical Center for Relapsing-Remitting Multiple Sclerosis

Search CenterWatch for Relapsing-Remitting Multiple Sclerosis

Inferred drug relations via UMLS63/NDF-RT42:

Genetic Tests for Relapsing-Remitting Multiple Sclerosis

About this section

Anatomical Context for Relapsing-Remitting Multiple Sclerosis

About this section
Sources:
34MalaCards
See all sources

MalaCards organs/tissues related to Relapsing-Remitting Multiple Sclerosis:

34
T cells, Brain, B cells, Thyroid, Testes, Bone, Spinal cord, Lung, Myeloid, Endothelial, Pituitary

Animal Models for Relapsing-Remitting Multiple Sclerosis or affiliated genes

About this section
Sources:
38MGI
See all sources

MGI Mouse Phenotypes related to Relapsing-Remitting Multiple Sclerosis:

38
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00036317.7HCRT, AQP4, IFNB1, NTF4, NOG
2MP:00053767.7IFNB1, NOG, AQP4, HCRT, MMP19
3MP:00053787.3NOG, HCRT, AQP4, MMP19, NTF4

Publications for Relapsing-Remitting Multiple Sclerosis

About this section
Sources:
53PubMed
See all sources

Articles related to Relapsing-Remitting Multiple Sclerosis:

(show top 50)    (show all 562)
idTitleAuthorsYear
1
Alemtuzumab-related thyroid dysfunction in a phase 2 trial of patients with relapsing-remitting multiple sclerosis. (24170099)
2014
2
Clinical and MRI predictors of response to interferon-beta and glatiramer acetate in relapsing-remitting multiple sclerosis patients. (23425504)
2013
3
How does fingolimod (gilenya(Ar)) fit in the treatment algorithm for highly active relapsing-remitting multiple sclerosis? (23641231)
2013
4
The patients with clinically isolated syndrome and relapsing remitting multiple sclerosis show different levels of advanced protein oxidation products and total thiol content in plasma and CSF. (23500606)
2013
5
Disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with daclizumab high-yield process in the SELECT study. (24022270)
2013
6
MR imaging and cognitive correlates of relapsing-remitting multiple sclerosis patients with cerebellar symptoms. (23271221)
2013
7
Width of 3. Ventricle: reference values and clinical relevance in a cohort of patients with relapsing remitting multiple sclerosis. (23730365)
2013
8
Reactivity to AQP4 epitopes in relapsing-remitting multiple sclerosis. (23673145)
2013
9
Segmented corpus callosum diffusivity correlates with the Expanded Disability Status Scale score in the early stages of relapsing-remitting multiple sclerosis. (24037007)
2013
10
Oral BG-12 (dimethyl fumarate) for relapsing-remitting multiple sclerosis: a review of DEFINE and CONFIRM. Evaluation of: Gold R, Kappos L, Arnold D, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012;367:1098-107; and Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012;367:1087-97. (23971970)
2013
11
Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the DEFINE study. (23797999)
2013
12
Improvement of Driving Skills in Persons With Relapsing-Remitting Multiple Sclerosis: A Pilot Study. (24161271)
2013
13
Natalizumab vs interferon beta 1a in relapsing-remitting multiple sclerosis: a head-to-head retrospective study. (22107083)
2012
14
Anti-CD25 (daclizumab) monoclonal antibody therapy in relapsing-remitting multiple sclerosis. (22284868)
2012
15
Investigation of autoantibody profiles for cerebrospinal fluid biomarker discovery in patients with relapsing-remitting multiple sclerosis. (22177943)
2012
16
Cost-effectiveness of fingolimod versus interferon beta-1a for relapsing remitting multiple sclerosis in the United States. (22583065)
2012
17
Treatments for relapsing-remitting multiple sclerosis: summarising current information by network meta-analysis. (22057838)
2012
18
Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis. (22797642)
2012
19
Influence of histocompatibility genes on disease susceptibility and treatment response in patients with relapsing-remitting multiple sclerosis treated with interferon I^-1a. (21785677)
2011
20
Vitamin D-related gene expression profiles in immune cells of patients with relapsing remitting multiple sclerosis. (21507492)
2011
21
Natalizumab for relapsing-remitting multiple sclerosis. (21193250)
2011
22
Social cognition impairments in relapsing-remitting multiple sclerosis. (22014035)
2011
23
Laquinimod: a promising oral medication for the treatment of relapsing-remitting multiple sclerosis. (21306281)
2011
24
Report of extracranial venous stenoses in relapsing-remitting multiple sclerosis patients. (21421808)
2011
25
Cerebellar information processing in relapsing-remitting multiple sclerosis (RRMS). (20714060)
2010
26
Serum and cerebrospinal fluid prolactin levels in male and female patients with clinically-isolated syndrome or relapsing-remitting multiple sclerosis. (20236233)
2010
27
A voxel-based morphometry study of disease severity correlates in relapsing-- remitting multiple sclerosis. (20028706)
2010
28
Symptom cluster and physical activity in relapsing-remitting multiple sclerosis. (20725947)
2010
29
Cortical lesions and atrophy associated with cognitive impairment in relapsing-remitting multiple sclerosis. (19752305)
2009
30
Switching to second-line therapies in interferon-beta-treated relapsing-remitting multiple sclerosis patients. (19129705)
2009
31
Neurobiological mechanisms underlying emotional processing in relapsing-remitting multiple sclerosis. (19420090)
2009
32
Immunomodulator therapy migration in relapsing remitting multiple sclerosis: a study of 152 cases. (18392406)
2008
33
Long-term adherence to interferon beta therapy in relapsing-remitting multiple sclerosis. (18057899)
2008
34
Cognitive impairment in relapsing-remitting multiple sclerosis can be predicted by imaging performed several years earlier. (17986503)
2008
35
Oral fumarate for relapsing-remitting multiple sclerosis. (18970966)
2008
36
Therapeutic outcome 3 years after switching of immunomodulatory therapies in patients with relapsing-remitting multiple sclerosis in Argentina. (18353125)
2008
37
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. (18713578)
2008
38
Campath 1-H treatment in patients with aggressive relapsing remitting multiple sclerosis. (18283404)
2008
39
Quality Assessment in Multiple Sclerosis Therapy (QUASIMS): a comparison of interferon beta therapies for relapsing-remitting multiple sclerosis. (17273808)
2007
40
Comparison of interferon beta products and azathioprine in the treatment of relapsing-remitting multiple sclerosis. (18074075)
2007
41
Outcome of beta-interferon treatment in relapsing-remitting multiple sclerosis: a Bayesian analysis. (17694348)
2007
42
Natalizumab: A new treatment for relapsing remitting multiple sclerosis. (18360634)
2007
43
Upper cervical spinal cord cross-sectional area in relapsing remitting multiple sclerosis: application of a new technique for measuring cross-sectional area on magnetic resonance images. (17659556)
2007
44
Interferon-beta treatment and active replication of the JC virus in relapsing-remitting multiple sclerosis patients. (17250736)
2007
45
Ipsilateral silent period: a marker of callosal conduction abnormality in early relapsing-remitting multiple sclerosis? (17011585)
2006
46
Cervical cord magnetization transfer ratio and clinical changes over 18 months in patients with relapsing-remitting multiple sclerosis: a preliminary study. (17086915)
2006
47
Serum levels of anti-myelin antibodies in relapsing-remitting multiple sclerosis patients during different phases of disease activity and immunomodulatory therapy. (15920290)
2005
48
Upregulation of the apoptosis regulators cFLIP, CD95 and CD95 ligand in peripheral blood mononuclear cells in relapsing-remitting multiple sclerosis. (12576232)
2003
49
A comparison of the biologic activity of two recombinant IFN-beta preparations used in the treatment of relapsing-remitting multiple sclerosis. (12581490)
2002
50
Occurrence of thyroid autoimmunity in relapsing remitting multiple sclerosis patients undergoing interferon-beta treatment. (10935838)
1998

Variations for Relapsing-Remitting Multiple Sclerosis

About this section

Expression for genes affiliated with Relapsing-Remitting Multiple Sclerosis

About this section
Sources:
2BioGPS, 16Gene Expression Omnibus DataSets
See all sources
Expression patterns in normal tissues for genes affiliated with Relapsing-Remitting Multiple Sclerosis

Search GEO for disease gene expression data for Relapsing-Remitting Multiple Sclerosis.

Pathways for genes affiliated with Relapsing-Remitting Multiple Sclerosis

About this section
Sources:
51PathCards, 61Thomson Reuters
See all sources

Pathways related to Relapsing-Remitting Multiple Sclerosis according to GeneCards/GeneDecks:

idSuper pathways (with members indented)ScoreTop Affiliating Genes
1
Show member pathways
Transcription NF kB signaling pathway61
Immune response Toll like receptor TLR ligands and common TLR signaling pathway leading to cell proinflammatory response61
9.7IFNB1, CXCL11

Compounds for genes affiliated with Relapsing-Remitting Multiple Sclerosis

About this section
Sources:
46Novoseek, 30IUPHAR, 25HMDB, 3BitterDB, 52PharmGKB, 12DrugBank
See all sources

Compounds related to Relapsing-Remitting Multiple Sclerosis according to GeneCards/GeneDecks:

(show all 14)
idCompoundScoreTop Affiliating Genes
1tarc469.8CXCL11, IFNB1
2ccl346 3010.8IFNB1, CXCL11
3ccl446 3010.8IFNB1, CXCL11
4quinolinic acid46 2510.7NTF4, HCRT
5histamine46 30 2511.1NTF4, AQP4, HCRT
6azathioprine46 3 52 1212.0IFNB1, NOG
7adenylate469.0NTF4, IFNB1, HCRT
8glutamate468.8HCRT, AQP4, IFNB1, NTF4
9oligonucleotide468.8HCRT, AQP4, CXCL11, IFNB1
10dopamine46 30 25 1211.7HCRT, IFNB1, NOG
11retinoic acid46 259.6AQP4, IFNB1, NTF4, NOG
12tyrosine468.3NOG, NTF4, IFNB1, HCRT
13dexamethasone46 52 30 1211.0NOG, IFNB1, CXCL11, AQP4, HCRT
14calcium46 52 25 1210.6HCRT, MMP19, CXCL11, IFNB1, NTF4, NOG

GO Terms for genes affiliated with Relapsing-Remitting Multiple Sclerosis

About this section
Sources:
17Gene Ontology
See all sources

Cellular components related to Relapsing-Remitting Multiple Sclerosis according to GeneCards/GeneDecks:

idNameGO IDScoreTop Affiliating Genes
1extracellular spaceGO:0056158.5NOG, IFNB1, CXCL11, IGHG3
2extracellular regionGO:0055766.7NOG, IGHG3, HCRT, MMP19, CXCL11, IFNB1

Products for genes affiliated with Relapsing-Remitting Multiple Sclerosis

About this section
  • Antibodies
  • Proteins
  • Lysates
  • Antibodies

Sources for Relapsing-Remitting Multiple Sclerosis

About this section
4CDC
14ExPASy
15FMA
23GTR
24HGMD
25HMDB
26ICD10
27ICD10 via Orphanet
28ICD9CM
30IUPHAR
31KEGG
36MeSH
37MESH via Orphanet
38MGI
41NCIt
42NDF-RT
45NINDS
46Novoseek
48OMIM
49OMIM via Orphanet
53PubMed
54QIAGEN
60SNOMED-CT via Orphanet
63UMLS
64UMLS via Orphanet